85-1400-79　GABA Receptor A, alpha 1, Human (Gamma-aminobutyric Acid Receptor Type A alpha 1 Subunit, GAA1) Control Peptide 100ug　G1015-06H

特徴

• Control Peptide for G1015-06D (antiserum) and G1015-06E (affinity purified antibody). Synthetic peptide 15aa sequence near the cytoplasmic, C-terminus of human GAA1.
• Synthetic peptide 15aa sequence near the cytoplasmic, C-terminus of human GAA1. No significant homology is detected with other GABA A receptor subtypes or other receptors. Species Crossreactivity: Mouse, rat, bovine and chicken.
• GABA (g-amino butyric acid) is the most abundant neurotransmitter in mammalian brain. GABA exerts its effects through ionotropic ligand-gated GABA-A, GABA-C and GABA-B receptors (GABAbetaRs). A family of GABA-A receptors subtypes exists. These receptors are generated by alternative splicing of alpha 1-6, beta 1-4, gamma 1-4, delta, epsilon, pie, theta and rho1-3 to form a heteromeric (pentameric) protein complexes. Various GABA-A subunits show distinct patterns of temporal and spatial expression that may imply its tissue specific physiological role (1). GABA A (GAA) receptor proteins (450-627aa) are characterized by the presence of a cleavable signal peptide, a large extracellular N-terminus, 3 TM (transmembrane) domains, a large cytoplasmic domain followed by TM4 and C-terminal extracellular domain. The regions between TM3-4 and the large cytoplasmic loop are least conserved among various GAA subunits. This variability may confer subunit specific functionality. GAA genes are distributed as clusters throughout the human genome (chromosomes 4, 5, 15 and X; delta subunit on chromosome 1). Human GAA1 (chromosome 5q34-q35) protein is 456aa (rat/mouse: 455aa). Defects in GABRA1 are a cause of Juvenile Myoclonic Epilepsy (JME), a common epileptic syndrome characterized by febrile seizures, onset in adolescence (rather than in childhood) and myoclonic jerks. GAA in the brain are the targets of many clinically important drugs.
• Applications:Suitable for use in ELISA and Antibody Blocking. Not suitable for use Western Blot due to low molecular weight. Other applications not tested.
• Recommended Dilution:ELISA: 0.5-1ug/ml. Coat plates at 1ug/ml with control peptide
• Antibody Blocking: 5-10ug per 1ul G1015-06D (antiserum) or per 1ug G1015-06E (affinity purified antibody)
• Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4°C for short-term only. For long-term storage, store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.